Vericel Corp
NASDAQ:VCEL

Watchlist Manager
Vericel Corp Logo
Vericel Corp
NASDAQ:VCEL
Watchlist
Price: 56.47 USD -0.05%
Market Cap: 2.8B USD
Have any thoughts about
Vericel Corp?
Write Note

Vericel Corp
Selling, General & Administrative

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Vericel Corp
Selling, General & Administrative Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Selling, General & Administrative CAGR 3Y CAGR 5Y CAGR 10Y
Vericel Corp
NASDAQ:VCEL
Selling, General & Administrative
-$138.6m
CAGR 3-Years
-16%
CAGR 5-Years
-19%
CAGR 10-Years
-31%
Abbvie Inc
NYSE:ABBV
Selling, General & Administrative
-$14B
CAGR 3-Years
-5%
CAGR 5-Years
-15%
CAGR 10-Years
-9%
Gilead Sciences Inc
NASDAQ:GILD
Selling, General & Administrative
-$5.6B
CAGR 3-Years
-2%
CAGR 5-Years
-6%
CAGR 10-Years
-8%
Amgen Inc
NASDAQ:AMGN
Selling, General & Administrative
-$7.5B
CAGR 3-Years
-9%
CAGR 5-Years
-8%
CAGR 10-Years
-5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Selling, General & Administrative
-$1.5B
CAGR 3-Years
-22%
CAGR 5-Years
-19%
CAGR 10-Years
-17%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Selling, General & Administrative
-$2.9B
CAGR 3-Years
-23%
CAGR 5-Years
-16%
CAGR 10-Years
-21%
No Stocks Found

Vericel Corp
Glance View

Market Cap
2.8B USD
Industry
Biotechnology

Vericel Corporation, nestled in the bustling hub of biomedical innovation in Cambridge, Massachusetts, has carved out a niche in the realm of advanced cell therapies. Founded in the late 1980s, the company initially focused on regenerative medicine but has since honed its expertise on the development and commercialization of cell-based treatments for patients with serious medical conditions. Vericel's journey is underpinned by its flagship product lines like MACI® and Epicel®, which illustrate its commitment to technological advancement and improving patient outcomes. MACI®, a matrix-applied autologous cultured chondrocyte technology, is designed to repair cartilage defects in the knee, often providing relief to those who suffer chronic pain from cartilage injuries. Epicel®, on the other hand, caters to patients with severe burns, utilizing a patient's own skin cells to regenerate skin and improve healing. These innovative solutions demonstrate Vericel's strategic pivot towards addressing niche, high-need areas within the orthopedic and burn treatment spaces. Vericel makes its revenue primarily through the sales of its proprietary treatments to hospitals and healthcare providers. The company's growth is closely tied to its ability to navigate the intricate regulatory landscapes associated with biologics, ensuring that its therapies meet the stringent requirements set forth by entities like the FDA. By targeting specific, high-impact markets with limited existing solutions, Vericel secures a competitive edge and commands significant pricing power, which enhances its financial performance. The company invests heavily in clinical trials and research to support and expand the use of its technologies, seeking indications for broader patient populations. Additionally, Vericel is continually working to optimize its manufacturing processes to scale its operations effectively without compromising the quality and efficacy of its treatments. Through strategic partnerships and a focus on innovation, Vericel is poised to leverage its scientific expertise to further entrench its position within the specialized markets it serves.

VCEL Intrinsic Value
31.18 USD
Overvaluation 45%
Intrinsic Value
Price

See Also

What is Vericel Corp's Selling, General & Administrative?
Selling, General & Administrative
-138.6m USD

Based on the financial report for Sep 30, 2024, Vericel Corp's Selling, General & Administrative amounts to -138.6m USD.

What is Vericel Corp's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-31%

Over the last year, the Selling, General & Administrative growth was -18%. The average annual Selling, General & Administrative growth rates for Vericel Corp have been -16% over the past three years , -19% over the past five years , and -31% over the past ten years .

Back to Top